Acknowledgements
We thank Fabian Bohländer and Ulrike Wippermann for critical reading of the manuscript. We also thank the investigators and sub-investigators from the 24 sites in Germany (Halle/Saale, Tübingen, Berlin, Erfurt, Wuppertal, Chemnitz, Hamburg, Frankfurt/Main, Köln, Stuttgart), Spain (Barcelona, Valencia, Girona, Tarragona, Madrid, Mataró, Palma de Mallorca, Terrassa, Sabadell) and United Kingdom (London, Poole, Cardiff) that actively participated in the phase II CIGMA trial as well as investigators and sub-investigators that participated in the phase I study of trimodulin (Wuppertal, Germany) for their trial conduct and data collection. We also thank SGS Laboratory (formerly INTERLAB Central lab services/Synlab, Munich, Germany), the local laboratory at the Helios clinic in Wuppertal, Germany, and Laboratoriumsmedizin MVZ Leverkusen, Germany for sample analysis. Medical writing support was provided by Abigail Adams and Julia Heagerty associated with Elements Communications Ltd, London, UK and funded by Biotest AG.